Q/C Technologies, Inc. income statement QCLS

Annual Quarterly

It recorded a net loss of $11.6 million. Diluted earnings per share were -$8.66. Over the twelve months ended Jun 30, 2020, revenue was $862,026 and the net loss was $4.3 million. Across the 4 fiscal years shown, revenue shrank from $3.0 million in fiscal 2016 to $1.6 million in fiscal 2019, about 18.9% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line	FY 2020 Jun 30, 2020	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017	FY 2016 Dec 31, 2016
Revenue	1 -54.9%	—	—	—	—	—	—	2 -5.3%	2 -50.4%	3 +13.3%	3 +40.0%
Cost of revenue	0 -73.6%	—	—	—	—	—	—	0 -50.3%	0 -31.3%	0 -1.8%	0 +20.1%
Gross profit	-0 -162.9%	—	—	—	—	—	—	0 +276.1%	0 -86.6%	1 -49.5%	2 +61.3%
Research and development	5 +781.6%	3 +0.9%	3 -56.3%	8 -13.2%	9 +34.4%	7 +173.4%	2 +791.3%	0 -74.0%	1 -15.6%	1 +6.0%	1 -15.5%
Selling, general and administrative	2 -60.0%	4 -10.2%	4 -23.5%	5 -1.4%	6 -14.0%	6 +116.2%	3 -12.6%	3 -54.4%	7 +21.5%	6 +22.8%	5 -24.0%
Operating income	-4 +51.5%	-10 +3.2%	-10 +40.6%	-17 -12.0%	-15 +47.0%	-29 -203.6%	-9 -173.3%	-3 +65.5%	-10 -52.1%	-7 -98.7%	-3 +65.6%
Other income (expense)	0 -82.8%	-2 +86.5%	-13 -200.5%	13 +15261.8%	0 +107.9%	-1 -765587.9%	0 -99.8%	0 -88.5%	1 +4.8%	1 +2898.4%	0 +124.9%
Pretax income	-4 +56.6%	-12 +50.2%	-23 -484.0%	-4 +73.7%	-15 +49.2%	-30 -215.0%	-9 -180.6%	-3 +68.8%	-11 -47.3%	-7 -123.0%	-3 +65.5%
Net income	-4 +50.7%	-12 +50.2%	-23 -484.0%	-4 +73.7%	-15 +49.2%	-30 -215.0%	-9 -144.0%	-4 +64.2%	-11 -47.3%	-7 -123.0%	-3 +64.5%
Net income to common	—	-15 +44.8%	-27 -230.5%	-8	—	—	—	—	11 +47.3%	7 +123.0%	3 -64.5%
Basic EPS	—	-8.66 +99.2%	-1,080.87 -20179.0%	-5.33 +54.6%	-11.74	—	—	—	—	—	—
Diluted EPS	—	-8.66 +99.2%	-1,080.87 -20179.0%	-5.33	—	—	—	—	—	—	—
Weighted average shares, basic	—	2 +6784.3%	0 -98.4%	2 +19.2%	1	—	—	—	—	—	—
Weighted average shares, diluted	—	2 +6784.3%	0 -98.4%	2	—	—	—	—	—	—	—
Other measures
Depreciation and amortization	0 -42.8%	—	—	—	—	—	0 -60.2%	0 -68.4%	0 -6.2%	0 -12.7%	0 -4.6%
EBITDA	-4 +51.6%	—	—	—	—	—	-9 -178.4%	-3 +65.4%	-10 -54.4%	-6 -109.2%	-3 +67.6%
Margins
Gross margin	-37.18%	—	—	—	—	—	—	30.36%	7.64%	28.28%	63.42%
Operating margin	-439.34%	—	—	—	—	—	—	-220.17%	-604.02%	-197.15%	-112.42%
Pretax margin	-434.59%	—	—	—	—	—	—	-214.41%	-651.37%	-219.58%	-111.57%
Profit margin	-493.40%	—	—	—	—	—	—	-246.55%	-651.37%	-219.58%	-111.57%
EBITDA margin	-435.96%	—	—	—	—	—	—	-215.47%	-589.94%	-189.70%	-102.75%

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: In Vitro & In Vivo Diagnostic Substances (SIC 2835)
Listed as: QCLS (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: New York, NY
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1321834
Former names: Q/C TECHNOLOGIES, INC. (until Oct 2, 2026); TNF Pharmaceuticals, Inc. (until Sep 10, 2025); MyMD Pharmaceuticals, Inc. (until Jul 1, 2024); Akers Biosciences, Inc. (until Apr 16, 2021); Akers Biosciences Inc (until Apr 11, 2017)

Other In Vitro & In Vivo Diagnostic Substances companies

All 21 In Vitro & In Vivo Diagnostic Substances companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.